Project UpdateJun 16, 2026, 09:01 AM
Creative Medical launches nationwide AI-driven BioDefense for 1,000 veterans
AI Summary
Creative Medical Technology Holdings announced the next operational milestone for Project PHOENIX, its regulatory-approved, AI-driven CELZ-Biodefense Regenerative BioDefense Initiative. The program is now moving into nationwide virtual participant onboarding and data collection, designed to support an initial cohort of at least 1,000 U.S. veterans exposed to toxic hazards. The platform leverages a decentralized mobile-app model and field-capable logistics, integrating multi-omics profiling and AI to identify biomarkers and therapeutic targets for drug discovery, all while utilizing existing infrastructure for capital efficiency.
Key Highlights
- Project PHOENIX advances to nationwide virtual onboarding for veterans.
- Platform designed to support an initial cohort of at least 1,000 veterans.
- Utilizes AI-enabled mobile-app data collection and field-capable logistics.
- Integrates multi-omics profiling with AI for biomarker and target discovery.
- Developing CELZ-Biodefense Toxic Exposure Atlas™ for drug discovery.
- Program leverages existing infrastructure, not requiring additional fundraising.
Price Impact
More from CELZ